{"id":389096,"date":"2023-12-26T00:00:00","date_gmt":"2023-12-26T00:00:00","guid":{"rendered":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/dlsfon0010-2023-biopharma-squamous-cell-carcinoma-of-the-head-and-neck-disease-landscape-forecast-g7-2023\/"},"modified":"2026-03-31T10:31:22","modified_gmt":"2026-03-31T10:31:22","slug":"dlsfon0010-2023-biopharma-squamous-cell-carcinoma-of-the-head-and-neck-disease-landscape-forecast-g7-2023","status":"publish","type":"report","link":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/dlsfon0010-2023-biopharma-squamous-cell-carcinoma-of-the-head-and-neck-disease-landscape-forecast-g7-2023\/","title":{"rendered":"Squamous Cell Carcinoma of the Head and Neck | Disease Landscape &#038; Forecast | G7 | 2023"},"content":{"rendered":"<p>The approval of the immune checkpoint inhibitors Keytruda (Merck &#038; Co.) and Opdivo (Bristol Myers Squibb) for recurrent and metastatic disease has transformed the SCCHN therapy market, which is continuing to evolve and grow beyond the EGFR inhibitor Erbitux (Eli Lilly \/ Merck KGaA) and chemotherapy-based regimens. We anticipate label expansions of current therapies and the launch of four emerging therapies with diverse mechanisms of action during the 2022-2032 forecast period. These events will drive rapid growth in the SCCHN therapy market, increase the drug-treatable population, and revolutionize the treatment landscape, particularly for locoregionally advanced non-nasopharyngeal disease.<\/p>\n<p><strong>Questions answered <\/strong><\/p>\n<ul>\n<li>How large are the clinically and commercially relevant drug-treatable SCCHN populations, and how will drug-treatment rates change over the 2022-2032 forecast period?<\/li>\n<li>What are the key current therapies for locoregionally advanced and recurrent\/metastatic SCCHN in the major pharmaceutical markets, and how are they positioned in the treatment algorithm?<\/li>\n<li>What market and patient shares can agents in late-phase development for SCCHN expect to secure, and how will they shape the future of the SCCHN therapy market? What are interviewed experts\u2019 views on current and emerging late-phase therapies?<\/li>\n<li>What are the key drivers of and constraints on the SCCHN therapy market, and how will these factors change over the 10-year forecast period?<\/li>\n<\/ul>\n<p><strong>Product description <\/strong><\/p>\n<p>Disease Landscape &#038; Forecast provides comprehensive market intelligence with world-class epidemiology, keen insight into current treatment paradigms, in-depth pipeline assessments, and drug forecasts supported by detailed primary and secondary research.<\/p>\n<p><strong>Solution enhancements<\/strong><\/p>\n<p>Disease Landscape &#038; Forecast will be updated throughout the year to provide timely insights and analyses as material indication-specific news and events unfold.<\/p>\n","protected":false},"template":"","class_list":["post-389096","report","type-report","status-publish","hentry","report-gateway-biopharma","biopharma-therapy-areas-oncology","biopharma-therapy-areas-squamous-cell-carcinoma-of-the-head-and-neck","biopharma-geography-us","biopharma-date-975"],"acf":[],"publishpress_future_workflow_manual_trigger":{"enabledWorkflows":[]},"_links":{"self":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/389096","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report"}],"about":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/types\/report"}],"version-history":[{"count":2,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/389096\/revisions"}],"predecessor-version":[{"id":576001,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/389096\/revisions\/576001"}],"wp:attachment":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/media?parent=389096"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}